Abstract: ［Abstract］  Objective〖HTSS〗〓To evaluate the efficacy and safety of ulinastatin combined with somatostatin in the treatment of digestive tract hemorrhage in neonates with digestive tract malformation.
〖HTH〗〖WTHZ〗Methods〖HTSS〗〓Fortytwo neonates with digestive tract hemorrhage after digestive tract malformation were selected. They were divided into control group and observation group according to the random number table, each with 21 cases. The control group was treated with somatostatin on the basis of routine hemostasis, and the observation group was treated with routine hemostasis+somatostatin+ulinastatin. The clinical efficacy and adverse reactions of the 2 groups were compared and analyzed.
〖HTH〗〖WTHZ〗Results〖HTSS〗〓the clinical curative effect of observation group than the control group, the total efficiency of treatment was higher than the control group(P＜0.05). Observation group of gastrointestinal decompression drainage test of occult blood clearance time was significantly shorter than the control group(P＜0.05), 24 h decrease in hemoglobin was significantly lower than the control group(P＜0.05). Adverse reactions of the 2 groups had no significant difference in the rate of total body the difference(P＞0.05).
〖HTH〗〖WTHZ〗Conclusion〖HTSS〗〓 Ulinastatin combined with somatostatin in the treatment of digestive tract hemorrhage in neonates with digestive tract hemorrhage has significant curative effect, and has no obvious adverse drug reactions. It is safe and worthy of clinical application 

Key words: gastrointestinal hemorrhage； ulinastatin, somatostatin, infant, newborn